a(CHEBI:rosiglitazone) causesNoChange a(HBP:HBP00018)

View Subject View Object

PubMed:21718217

Pedersen and Flynn examined the effects of rosiglitazone and found that activation of PPAR-g ameliorated behavioral deficits in the Tg2576 AD mouse model. However, these animals displayed no changes in plaque pathology, but had reduced brain Ab42 levels.

Related Edges 3

• a(CHEBI:rosiglitazone) increases act(p(HGNC:PPARG))
• a(CHEBI:rosiglitazone) increases bp(GO:behavior)
• a(CHEBI:rosiglitazone) decreases a(CHEBI:"amyloid-beta polypeptide 42")

Confidence

High

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---